Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

1,002

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

September 21, 2017

Study Completion Date

March 12, 2018

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

IPV-Al SSI

3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age

BIOLOGICAL

IPV SSI

3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age

Trial Locations (1)

Unknown

5 sites in Philippines, Manila

Sponsors
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Larix A/S

INDUSTRY

collaborator

Syneos Health

OTHER

collaborator

AJ Vaccines A/S

INDUSTRY

lead

Statens Serum Institut

OTHER